No Data
No Data
Buy Rating on Day One Biopharmaceuticals: Ojemda's Market Potential and Strategic Commercialization
Day One Biopharm Is Maintained at Buy by HC Wainwright & Co.
Day One Biopharm Is Maintained at Buy by HC Wainwright & Co.
Express News | Day One Biopharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $40 From $50
Express News | Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $33 Price Target
Day One Biopharmaceutical Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 98.19% Needham → $33 Reiterates Buy → Buy 04/25/2024 98.19% Needham → $33 Reiterates Buy → Buy
Express News | Day One Biopharmaceuticals Inc Q1 Shr View $-0.66 -- Lseg Ibes Data
J L 7 2 : 为啥股票还是软趴趴 没力向上呢
73125363 J L 7 2: 在蓄力吧
Master Corgi : Your pic gained you many followers
Vijay Raja : BEQVEZ has the same problem that Roctavian has. Payers have not been sorted . Very slow uptake.